These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11839516)

  • 1. William Pardridge discusses the lack of BBB research. Interview by Rebecca N. Lawrence.
    Pardridge WM
    Drug Discov Today; 2002 Feb; 7(4):223-6. PubMed ID: 11839516
    [No Abstract]   [Full Text] [Related]  

  • 2. Antisense and sensibility.
    Dove A
    Nat Biotechnol; 2002 Feb; 20(2):121-4. PubMed ID: 11821852
    [No Abstract]   [Full Text] [Related]  

  • 3. Blood-brain barrier drug targeting: the future of brain drug development.
    Pardridge WM
    Mol Interv; 2003 Mar; 3(2):90-105, 51. PubMed ID: 14993430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sir Richard Sykes contemplates the future of the pharma industry. Interview by Rebecca N Lawrence.
    Lawrence RN
    Drug Discov Today; 2002 Jun; 7(12):645-8. PubMed ID: 12110238
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis.
    Alves OL; Doyle AJ; Clausen T; Gilman C; Bullock R
    Ann N Y Acad Sci; 2003 May; 993():25-34; discussion 48-53. PubMed ID: 12853292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotrophins, neuroprotection and the blood-brain barrier.
    Pardridge WM
    Curr Opin Investig Drugs; 2002 Dec; 3(12):1753-7. PubMed ID: 12528312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long march of antisense.
    Jones D
    Nat Rev Drug Discov; 2011 Jun; 10(6):401-2. PubMed ID: 21629279
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of the blood brain barrier in neurodegenerative disorders and their treatment.
    Palmer AM
    J Alzheimers Dis; 2011; 24(4):643-56. PubMed ID: 21460432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense as a neuroscience tool and therapeutic agent.
    Estibeiro P; Godfray J
    Trends Neurosci; 2001 Nov; 24(11 Suppl):S56-62. PubMed ID: 11881747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting neurotherapeutic agents through the blood-brain barrier.
    Pardridge WM
    Arch Neurol; 2002 Jan; 59(1):35-40. PubMed ID: 11790228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penetration of dynorphin 1-13 across the blood-brain barrier.
    Turner TD; Browning JL; Widmayer MA; Baskin DS
    Neuropeptides; 1998 Apr; 32(2):141-9. PubMed ID: 9639252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amelioration by cyclosporin A of brain damage in transient forebrain ischemia in the rat.
    Uchino H; Elmér E; Uchino K; Li PA; He QP; Smith ML; Siesjö BK
    Brain Res; 1998 Nov; 812(1-2):216-26. PubMed ID: 9813336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotection in experimental stroke with targeted neurotrophins.
    Wu D
    NeuroRx; 2005 Jan; 2(1):120-8. PubMed ID: 15717063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior neuroprotective efficacy of a novel antioxidant (U-101033E) with improved blood-brain barrier permeability in focal cerebral ischemia.
    Schmid-Elsaesser R; Zausinger S; Hungerhuber E; Plesnila N; Baethmann A; Reulen HJ
    Stroke; 1997 Oct; 28(10):2018-24. PubMed ID: 9341713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stroke treatment--light at the end of the tunnel?
    Garber K
    Nat Biotechnol; 2007 Aug; 25(8):838-40. PubMed ID: 17687351
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro blood-brain barrier permeability and cerebral endothelial cell uptake of the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions.
    Dehouck MP; Cecchelli R; Richard Green A; Renftel M; Lundquist S
    Brain Res; 2002 Nov; 955(1-2):229-35. PubMed ID: 12419541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins.
    Pardridge WM
    Adv Exp Med Biol; 2002; 513():397-430. PubMed ID: 12575830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute stroke therapy: translating preclinical neuroprotection to therapeutic reality.
    Parsons AA; Irving EA; Legos JJ; Lenhard SC; Chandra S; Schaeffer TR; Haimbach RE; White RF; Hunter AJ; Barone FC
    Curr Opin Investig Drugs; 2000 Dec; 1(4):452-63. PubMed ID: 11249699
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of neuroprotective compounds in the pharmaceutical industry: where are we, and where are we going?
    Santilli N
    Prog Brain Res; 2002; 135():497-507. PubMed ID: 12143368
    [No Abstract]   [Full Text] [Related]  

  • 20. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector.
    Song BW; Vinters HV; Wu D; Pardridge WM
    J Pharmacol Exp Ther; 2002 May; 301(2):605-10. PubMed ID: 11961063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.